Understanding May 29 2026 This Week In Cardiology
If you are looking for information about May 29 2026 This Week In Cardiology, you have come to the right place. A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in
Key Takeaways about May 29 2026 This Week In Cardiology
- Listener feedback on valvular heart disease, statins and frailty, left atrial posterior wall ablation fails again, interpreting medical ...
- Listener feedback, transcatheter tricuspid valve replacement, a new metabolic disease called CKM, the ARISE-FLUIDS Trial, the ...
- John Mandrola offers an ACC recap of 5 big trials—Hi-PEITHO, PROTAVI, ORBITA-CTO, CHIPS-BCIS3 and CHAMPION AF This ...
- PCSK9 inhibitors in high-risk diabetes without ASCVD, the CAAN-AF trial, conduction system pacing vs biventricular pacing, PFA ...
- Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, ...
Detailed Analysis of May 29 2026 This Week In Cardiology
Time to quadruple therapy, the disappointing AVANT GUARD trial, PFA risks, the TREAT-PVC trial, and NSTEMI care in the frail ... Three more digoxin trials, yet another GLP-1 drug on the horizon, vagal nerve stimulation, trial inside baseball, and more on lipid ... Listener feedback, the huge CLOSURE-AF trial of LAAC vs best medical therapy, previews of CHAMPION AF, and the ...
Early aortic valve replacement in aortic stenosis, left atrial appendage occlusion in JAMA
We hope this detailed breakdown of May 29 2026 This Week In Cardiology was helpful.